Chugai Pharmaceutical Q4 2025 Earnings Results & Report

Chugai Pharmaceutical EPS Results

• Actual EPS: $0.25
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Chugai Pharmaceutical Revenue Results

• Actual Revenue: $2.25 billion
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Chugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer. The company also develops antibody-based therapies and other biologic and small-molecule medicines.

Founded in 1925 and headquartered in Tokyo, Chugai operates primarily in Japan while serving international markets through its global business and strategic relationship with Roche. Chugai and Roche have maintained a strategic alliance since 2002, under which Roche distributes certain Chugai-developed products internationally and Chugai markets selected Roche products in Japan. Chugai is listed in Japan, and its American depositary shares trade over the counter under the symbol CHGCY.